Pricing and Reimbursement Application Tracker
Login
Search
durvalumab in combination with platinum-based chemotherapy (Imfinzi® in combination with platinum-based chemotherapy)
Application Details
HSE Application ID
HSE100095
HTA Number
HTA Link
Drug
durvalumab in combination with platinum-based chemotherapy
Brand
Imfinzi® in combination with platinum-based chemotherapy
Applicant
AstraZeneca
Indication Applied For
Durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy as adjuvant treatment, indicated for the treatment of adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no EGFR mutations or ALK rearrangements.
Application Date
18/03/2026
Marketing Authorisation Date
31/03/2025
Application Status
Pricing and Reimbursement Application Complete
18/03/2026
Rapid Review Commissioned
13/03/2026
New Search
Status
Pricing and Reimbursement Application Complete
Rapid Review Commissioned
Rapid Review Completed
Applicant Meeting Held with CPU
Awaiting Proposal from Applicant
Proposal from Applicant Under Review
Full Health Technology Assessment Commissioned by HSE
NCPE Assessment Completed
HSE Drugs Group Review Pending
Reviewed by HSE Drugs Group
HSE Rare Disease Technology Review Committee - Review Requested
HSE Rare Disease Technology Review Committee - Review Received
Further Information Requested by HSE Drugs Group
Reviewed by HSE Senior Leadership Team
Managed Access Protocol (MAP) Commissioned
Proposed HSE Decision Issued to Applicant
Applicant Representations Received
HSE Decision Issued to Applicant
Application On Hold at the Request of Applicant
Application Withdrawn at the Request of Applicant
Application on Hold as Agreed by HSE and Applicant
HSE Approval Letter Issued to Applicant
Full Health Technology Assessment Submitted to NCPE
Delete Application
×
Are you sure you want to delete this Application?
Once it's deleted it cannot be retrieved.
Remove Status and Date
×
Are you sure you want to delete this?